[Figure 1] Seegene unveils world's first commercialized '3 Ct' PCR assay

PR95670

SEOUL, South Korea, April 26, 2022 /PRNewswire=KYODO JBN/ --

-Provides Ct value of three targets in one channel; '3 Ct' PCR assay to launch

in H1

-"Dream MDx technology" developed based on Seegene's 20-year expertise;

combines 19 different patented technologies, including DPO(TM), TOCE(TM),

MuDT(TM)-'3 Ct' to lay foundation for automated syndromic testing and make MDx

more accessible

Seegene Inc. (KQ096530), South Korea's leading molecular diagnostics (MDx)

company, today announced the development of the world's first commercialized

PCR assay applying '3 Ct' technology. The 'Allplex(TM) HPV HR Detection' was

showcased at the 2022 European Congress of Clinical Microbiology and Infectious

Diseases (ECCMID) held April 23-26 in Lisbon, Portugal.

In a polymerase chain reaction (PCR), the cycle threshold (Ct) value is used to

quantify the concentration of a viral DNA sequence (the target). Due to

technological limitations, the conventional real-time PCR technique finds the

Ct value of one target in one channel.

But Seegene's '3 Ct' technology can provide the Ct value of three targets in

one channel without compromising sensitivity and specificity. The successful

development is based on Seegene's 20-year expertise and combines 19 different

patented technologies, including DPO(TM), TOCE(TM), and MuDT(TM). Using five

channels in a single tube, Seegene can provide quantitative data for a total of

15 targets. '3 Ct' has been dubbed the "dream MDx technology."

The company plans to apply '3 Ct' technology to its entire product line-up,

including respiratory virus (RV), sexually transmitted infection (STI),

gastrointestinal infection (GI), and urinary tract infection (UTI) assays.

Seegene expects '3 Ct' technology to take syndromic testing to another level.

By detecting the causative pathogen, level of infection, and potential of

co-infection, it will help determine the priority of treatment and enhance

patient management. '3 Ct' technology also increases testing capacity. Such

features are expected to improve the service and cost-structure of the medical

sector once '3 Ct' technology is widely utilized.

Seegene's first '3 Ct' technology applied product, Allplex(TM) HPV HR

Detection, is designed to detect 14 high-risk human papillomavirus (HPV) types

that can cause cervical cancer (See figure 1). It also provides the individual

Ct value of each of the types allowing quantitative analysis regarding

infection level. Early detection of HPV contributes to the prevention and

management of cervical cancer. HPV products from other industry players provide

individual Ct values for two high-risk types, HPV 16 and 18.

The Allplex™ HPV HR Detection, planned to be launched within the first half of

this year, will come with a significant cost advantage compared to existing HPV

products to increase accessibility to PCR testing, which had been difficult

previously due to high costs. The product will also be compatible with

Seegene's fully automated AIOS (all-in-one system). The company plans to

introduce the industry's first 'fully automated, mass, syndromic testing

system,' to lay the foundation for testing anywhere, including large hospitals,

C-Labs, and even small and medium-sized clinics, and make PCR testing part of

everyday life.

"HPV genotyping is essential for a good follow-up of a patient to observe the

emergence, persistence or clearance of each genotype," says HPV expert

Sebastien Hantz, Professor at the Faculty of Medicine at the University of

Limoges in France. "Seegene is a company very involved in the development of

molecular diagnostics tests for the detection of different pathogens. For

certain clinical situations, like respiratory infections, syndromic testing is

very useful."

SOURCE  Seegene Inc.

Image Attachments Links:

   Link: http://asianetnews.net/view-attachment?attach-id=419978

   Caption: [Figure 1] Seegene unveils world's first commercialized '3 Ct' PCR assay